Alteogen KRX:196170KOSDAQ
알테오젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h4
Articles, 7 days6
DART filings, 7 days0
Articles tracked6since Sep 11
In Q2 2026, Alteogen reported revenue of ₩68.9bn, up 269.5% year on year, and operating profit of ₩34.2bn. Alteogen (알테오젠) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 2 articles. The most common catalyst was contracts & orders (1). It was most often mentioned alongside ABL Bio.
Alteogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩68.9bn | +269.5% | ₩34.2bn | ₩30.0bn |
| Q1 2026 | ₩71.6bn | -14.5% | ₩39.3bn | ₩71.3bn |
| Q4 2025 derived | ₩64.5bn | +26.9% | ₩19.6bn | ₩74.4bn |
| Q3 2025 | ₩49.0bn | +902.3% | ₩26.7bn | ₩22.0bn |
| Q2 2025 | ₩18.6bn | +52.4% | −₩426m | −₩34.3bn |
| Q1 2025 | ₩83.7bn | +139.8% | ₩61.0bn | ₩83.0bn |
| Q4 2024 derived | ₩50.8bn | +127.4% | ₩23.0bn | ₩52.4bn |
| Q3 2024 | ₩4.9bn | -77.0% | −₩8.2bn | −₩9.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Alteogen top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
